Related Experiment Videos
Intracoronary streptokinase in evolving acute myocardial infarction
Insights
Intracoronary thrombolytic therapy, using agents like streptokinase, can reopen blocked arteries in acute myocardial infarction (AMI) patients. However, effectiveness and complication rates require further investigation through controlled trials.
Area of Science:
- Cardiology
- Interventional Cardiology
Background:
- Intracoronary thrombolytic agents, notably streptokinase, are used to recanalize occluded arteries in acute myocardial infarction (AMI).
- Previous uncontrolled trials suggest effectiveness in restoring coronary artery blood flow and improving left ventricular ejection fraction (LVEF).
- Widespread adoption of this therapy is based on reported success and low complication rates in prior studies.
Purpose of the Study:
- To evaluate the effectiveness and safety of intracoronary thrombolytic therapy in patients with evolving AMI.
- To compare initial outcomes with previously reported uncontrolled trial results.
Main Methods:
- Retrospective analysis of 23 patients with evolving AMI treated with intracoronary thrombolytic agents.
- Assessment of reperfusion rates, changes in LVEF, and incidence of complications.
Main Results:
- Reperfusion was achieved in 12 out of 23 patients.
- Only five of 17 survivors showed a significant improvement (≥10%) in LVEF.
- Complications included bleeding and allergic reactions to streptokinase.
Conclusions:
- Initial experience suggests lower efficacy and higher complication rates compared to previous reports.
- Controlled trials are necessary to critically assess the benefits and risks of intracoronary thrombolytic therapy in AMI.
Abstract:
Intracoronary application of thrombolytic agents, particularly streptokinase, can recanalize arteries that had been totally occluded in patients with evolving acute myocardial infarction (AMI). Numerous uncontrolled trials have testified to the effectiveness of thrombolytic therapy in most patients in reestablishing flow to the infarct-related coronary artery. Follow-up of patients in whom reperfusion has been established has often demonstrated small but significant increases in the left ventricular ejection fraction. In contrast, in other patients in whom thrombolytic therapy failed to reopen the occluded vessel, the left ventricular ejection fraction usually does not change during follow-up. In most reported uncontrolled trials, few complications are described and the mortality rate in patients treated by this therapy may be lower than expected. These data have been used as the basis for widespread application of this technique in many catheterization laboratories around the world. Our initial experience at the University of Florida in 23 patients has not been as successful as other uncontrolled trials previously reported. Reperfusion was accomplished in only 12 patients. Of 17 who survived their AMI, only five demonstrated an improved left ventricular ejection fraction of at least 10%. Serious complications, including bleeding from catheterization sites or allergic reactions to streptokinase, occurred. Controlled trials to critically evaluate this new therapy are needed and are in progress.